phrykt

NewAmsterdam Pharma Co N.V. (NAMS): who owns it and who trades it

As of Nov 16, 2026, NAMS insiders reported 42 open-market sales worth $63.3M and 1 purchase worth $226K in the last 12 months, with 2% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael H. Davidson (CEO), with $25.3M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling NewAmsterdam Pharma

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NAMS

194 funds and institutions reported NAMS shares worth $4.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Frazier Life Sciences Management, L.P. with 15.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Frazier Life Sciences Management, L.P.15.5%
Capital World Investors10.5%
FMR LLC (Fidelity)8.8%
Ra Capital Management, L.P.8.2%
Fcpm III Services B.v.7.3%
Deerfield Management Company, L.P.3.6%
Viking Global Investors LP3.6%
Bain Capital Life Sciences Investors, LLC3.3%
Maverick Capital Ltd2.8%
Duquesne Family Office LLC2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Frazier Life Sciences Management, L.P.18.09M15.47%$613M+7%
Capital World Investors12.23M10.46%$414M+10%
FMR LLC (Fidelity)10.34M8.84%$350M+18%
Ra Capital Management, L.P.9.55M8.17%$324MNo change
Fcpm III Services B.v.8.49M7.26%$288M-8%
Deerfield Management Company, L.P.4.26M3.65%$145MNo change
Viking Global Investors LP4.20M3.60%$142MNo change
Bain Capital Life Sciences Investors, LLC3.81M3.26%$129M-48%
Maverick Capital Ltd3.27M2.80%$111M+49%
Duquesne Family Office LLC3.07M2.63%$104MNo change
Jupiter Topco LLC2.54M2.17%$86M–
California State Teachers Retirement System2.28M1.95%$67.4M+4105%
Medicxi Ventures Management (Jersey) Ltd2.21M1.89%$74.9M-17%
Jennison Associates LLC2.10M1.80%$71.2M-24%
Orbis Allan Gray Ltd1.75M1.49%$59.2M–
Polar Capital Holdings Plc1.72M1.48%$58.4M-39%
Capital International Investors1.72M1.47%$58.4M+20%
Goldman Sachs Group Inc1.54M1.32%$52.4M-21%
Westfield Capital Management Co LP1.54M1.31%$52.1M-30%
Castle Hook Partners LP1.37M1.17%$46.5M+31%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NAMS insiders reported $226K of open-market purchases and $63.3M of sales. 2% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$226K
1 trades, 1 people
Sales, 12 months
$63.3M
42 trades, 6 people
Sales under a 10b5-1 plan
2%
Share of sale value
Latest trade
Sep 30, 2026
Filed Oct 2, 2026

Purchases and sales by month

$26M$26MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 30, 2026Johannes Jacob Pieter KasteleinDirectorSale plan50,246$25.03$1.3MForm 4
Sep 14, 2026Michael H. DavidsonCEOPurchase10,000$22.65$226KForm 4
Sep 4, 2026John W SmitherDirectorSale1,600$25.32$40.5KForm 4
Aug 24, 2026Johannes Jacob Pieter KasteleinDirectorSale125,000$26.91$3.4MForm 4
Jul 20, 2026Louise Frederika KooijChief Accounting OfficerSale2,915$31.71$92.4KForm 4
Jul 20, 2026Louise Frederika KooijChief Accounting OfficerSale31,885$31.05$990KForm 4
Jul 20, 2026Louise Frederika KooijChief Accounting OfficerSale70,200$29.96$2.1MForm 4
Jun 22, 2026Louise Frederika KooijChief Accounting OfficerSale300$30.73$9.2KForm 4
Jun 22, 2026Louise Frederika KooijChief Accounting OfficerSale39,700$30.20$1.2MForm 4
May 26, 2026Louise Frederika KooijChief Accounting OfficerSale65,000$35.69$2.3MForm 4
Mar 11, 2026Louis G LangeDirectorSale446$31.23$13.9KForm 4
Mar 11, 2026Louis G LangeDirectorSale44,173$30.41$1.3MForm 4
Mar 9, 2026Johannes Jacob Pieter KasteleinDirectorSale101,409$30.29$3.1MForm 4
Mar 6, 2026Louis G LangeDirectorSale28,186$29.41$829KForm 4
Mar 6, 2026Johannes Jacob Pieter KasteleinDirectorSale94,124$30.32$2.9MForm 4
Mar 5, 2026Johannes Jacob Pieter KasteleinDirectorSale104,467$30.30$3.2MForm 4
Mar 2, 2026Michael H. DavidsonCEOSale443,707$33.25$14.8MForm 4
Feb 26, 2026Michael H. DavidsonCEOSale165,408$33.63$5.6MForm 4
Feb 26, 2026Michael H. DavidsonCEOSale17,924$34.44$617KForm 4
Feb 25, 2026Michael H. DavidsonCEOSale46,517$35.11$1.6MForm 4
Feb 25, 2026Michael H. DavidsonCEOSale10,436$35.96$375KForm 4
Feb 25, 2026Michael H. DavidsonCEOSale1,300$36.68$47.7KForm 4
Feb 24, 2026Michael H. DavidsonCEOSale61,547$36.13$2.2MForm 4
Feb 24, 2026Michael H. DavidsonCEOSale3,161$36.46$115KForm 4
Feb 20, 2026Johannes Jacob Pieter KasteleinDirectorSale30,789$35.46$1.1MForm 4
Feb 20, 2026Johannes Jacob Pieter KasteleinDirectorSale14,692$35.00$514KForm 4
Jan 28, 2026Louise Frederika KooijChief Accounting OfficerSale32,612$31.80$1MForm 4
Jan 27, 2026Louise Frederika KooijChief Accounting OfficerSale39,816$32.62$1.3MForm 4
Jan 26, 2026Louise Frederika KooijChief Accounting OfficerSale34,091$32.77$1.1MForm 4
Jan 26, 2026Louise Frederika KooijChief Accounting OfficerSale309$33.45$10.3KForm 4
Jan 23, 2026Louise Frederika KooijChief Accounting OfficerSale25,405$33.44$850KForm 4
Jan 23, 2026Louise Frederika KooijChief Accounting OfficerSale12,767$34.37$439KForm 4
Jan 21, 2026Mayur Ian SomaiyaCFOSale24,362$33.80$823KForm 4
Jan 21, 2026Mayur Ian SomaiyaCFOSale15,422$33.25$513KForm 4
Jan 20, 2026Mayur Ian SomaiyaCFOSale19,604$32.38$635KForm 4
Jan 20, 2026Mayur Ian SomaiyaCFOSale39,712$31.78$1.3MForm 4
Jan 20, 2026Mayur Ian SomaiyaCFOSale900$30.64$27.6KForm 4
Jan 5, 2026Johannes Jacob Pieter KasteleinDirectorSale6,000$33.25$200KForm 4
Jan 5, 2026Louise Frederika KooijChief Accounting OfficerSale2,647$33.25$88KForm 4
Jan 5, 2026Mayur Ian SomaiyaCFOSale5,118$33.25$170KForm 4
Dec 26, 2025Louise Frederika KooijChief Accounting OfficerSale43,872$35.30$1.5MForm 4
Dec 24, 2025Louise Frederika KooijChief Accounting OfficerSale26,011$35.68$928KForm 4
Dec 23, 2025Louise Frederika KooijChief Accounting OfficerSale75,117$36.21$2.7MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Michael H. DavidsonChief Executive Officer, Director$226K$25.3MSep 14, 2026
Louise Frederika KooijChief Accounting Officer–$16.8MJul 20, 2026
Johannes Jacob Pieter KasteleinChief Scientific Officer, Director–$15.5MSep 30, 2026
Mayur Ian SomaiyaChief Financial Officer–$3.4MJan 21, 2026
Louis G LangeDirector–$2.2MMar 11, 2026
John W SmitherDirector–$40.5KSep 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NAMS short interest

High short interest. 10.0% of NAMS shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 68%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.01M NAMS shares were sold short, 10.0% of the shares outstanding, down 14.9% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

10.0%May 15Oct 3017.4%

Days to cover

8.3May 15Oct 3014.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.01M10.05%-15%1.44M8.3
Oct 15, 202614.11M11.80%-26%1.33M10.6
Sep 30, 202619.05M15.93%+22%2.03M9.4
Sep 15, 202615.66M13.10%+17%1.58M9.9
Aug 31, 202613.39M11.20%+6%1.00M13.4
Aug 14, 202612.65M10.59%+27%1.28M9.9
Jul 31, 20269.96M8.52%+9%1.02M9.8
Jul 15, 20269.18M7.85%+1%819,05711.2
Jun 30, 20269.09M7.78%-1%1.31M6.9
Jun 15, 20269.17M7.85%+13%1.26M7.3
May 29, 20268.10M6.93%+13%1.32M6.2
May 15, 20267.14M6.11%-9%1.92M3.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

NewAmsterdam Pharma company events

NewAmsterdam Pharma filed 13 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Sep 29, 2026.

  1. Sep 29, 2026AnnouncementNewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease. Filing
  2. Sep 21, 2026AnnouncementNewAmsterdam Pharma Company N.V. along with its partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Evlarco ® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination, or “FDC”) for patients with… Filing
  3. Aug 14, 2026LeadershipAmended an earlier report. As previously disclosed on July 22, 2026, Douglas Kling resigned as the Company’s Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company. Filing
  4. Aug 14, 2026LeadershipNewAmsterdam Pharma Company N.V. appointed Robert W. Gunning, age 55, as its principal accounting officer. Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jul 24, 2026AnnouncementNewAmsterdam Pharma Company N.V. issued a press release announcing that the Company and the Menarini Group have received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending marketing authorization for Ubeslo® (obicetrapib… Filing
  7. Jul 22, 2026LeadershipDouglas Kling notified NewAmsterdam Pharma Company N.V. that he would resign as the Company’s Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company. Filing
  8. Jun 3, 2026LeadershipNewAmsterdam Pharma Company N.V. held its 2026 annual general meeting of shareholders in Amsterdam, the Netherlands. Filing
  9. May 7, 2026ResultsReleased financial results. Filing
  10. Apr 24, 2026LeadershipNewAmsterdam Pharma Company N.V. and Louise Kooij agreed that her employment as the Company's Chief Accounting Officer would end effective August 31, 2026 (the “Separation Date“). Filing
  11. Mar 2, 2026AnnouncementShared information with investors. Filing
  12. Feb 18, 2026ResultsReleased financial results. Filing
  13. Jan 9, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

NewAmsterdam Pharma financials

Famous investors that hold NAMS

6 of the 50 well-known investors we track reported holding NAMS in their latest 13F filing. The largest position is Stanley Druckenmiller's, worth $81.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Stanley Druckenmiller · Duquesne Family OfficeQ3 20263.36M$81.6M2.0%+9%
Andreas Halvorsen · Viking Global InvestorsQ3 20262.46M$59.9M0.2%-41%
Lee Ainslie · Maverick CapitalQ3 20261.86M$45.1M0.4%-43%
Israel Englander · Millennium ManagementQ3 2026784,158$19.1M0.0%+56%
Ken Griffin · Citadel AdvisorsQ3 2026277,982$6.8M0.0%-57%
Paul Tudor Jones · Tudor Investment CorpQ3 202685,007$2.1M0.0%+7%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named NAMS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G7.5%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G7.5%
Nov 16, 2026RA Capital Management, L.P.13G/A9.9%
Nov 16, 2026RA Capital Management, L.P.13G/A9.9%
Nov 5, 2026FMR LLC13G/A10.0%
Nov 5, 2026FMR LLC13G/A10.0%

Questions about NewAmsterdam Pharma Co N.V. (NAMS) stock

Who owns the most NAMS stock?

The largest reported owner of NewAmsterdam Pharma Co N.V. (NAMS) is Frazier Life Sciences Management, L.P., with 15.5% of the company. In total, 194 funds and institutions reported holding NAMS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are NAMS insiders buying or selling?

In the last 12 months, NAMS insiders reported 1 open-market purchase worth $226K and 42 sales worth $63.3M. The latest trade was on Sep 30, 2026. See every trade.

What is the short interest in NAMS?

As of Oct 30, 2026, 12.01M NAMS shares were sold short, 10.0% of the shares outstanding, down 14.9% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold NAMS?

6 of the 50 well-known investors we track reported NAMS in their latest 13F filing, including Stanley Druckenmiller, Andreas Halvorsen, Lee Ainslie. The largest position is worth $81.6M. See all holders.

Executive pay

NewAmsterdam Pharma's chief executive was paid a total of $13.6M for the year ended Dec 31, 2025, up 111% from $6.5M the year before. In the last 12 months, NewAmsterdam Pharma's executives and directors bought $226K of stock on the open market and sold $63.3M.

Chief executive, total pay$13.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$30.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.